6Z

Linc ABFRA Linc Stock Report

Last reporting period 31 Dec, 2023

Updated 13 Nov, 2024

Last price

Market cap $B

0.493

Micro

Exchange

XFRA - Deutsche Boerse AG

6ZB.F Stock Analysis

6Z

Uncovered

Linc AB is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

99/100

Moderate score

Market cap $B

0.493

Dividend yield

Shares outstanding

57.91 B

Linc AB is an investment company that focuses on long-term share ownership in the Nordic life science market. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2021-05-28. Linc invests in product-oriented companies within the Nordic Life Science industry - primarily in pharmaceutical and medical technology companies. The investments are made in both private and public companies and in research and operational companies. Typically, investments in drug development take place in an earlier phase compared to investments in medical technology. Linc Invest is an active and long-term owner with a wide industrial network to support the portfolio companies. The firm works together with the management, founders and board to realize the inherent potential that exists in the investment, have ambitious plans for further development and expansion and actively participate in the nomination committee work.

View Section: Eyestock Rating